Medical and surgical treatment of Parkinson's disease - Strategies to slow symptom progression and improve quality of life

被引:8
作者
Conley, SC [1 ]
Kirchner, JT [1 ]
机构
[1] Lancaster Gen Hosp, Dept Family & Community Med, Family Practice Residency Program, Lancaster, PA 17604 USA
关键词
D O I
10.3810/pgm.1999.08.648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite new medical and surgical therapy, mortality rates for Parkin son's disease remain unchanged. Nevertheless, symptom progression can be slowed and quality of life improved with current methods of treatment. Levodopa is the most effective drug for Parkinson's disease, but its long-term use is associated with significant motor complications. Dopamine agonists hold promise because of more sustained stimulation of dopamine receptors and possibly an antioxidant effect. Selegiline, amantadine, and anticholinergics are still used but must be employed with caution in the elderly. COMT inhibitors may be useful adjuncts to levodopa therapy but are plagued with serious adverse effects. Goals of therapy in patients less than 60 years of:age include sparing levodopa therapy and providing neuroprotection. For patients 60 years and older goals include maintaining cognitive status and treating symptoms. Surgical treatment includes globus pallidus internal-segment pallidotomy, deep brain stimulation, and fetal nigral transplantation. These hold promise for the future.
引用
收藏
页码:41 / +
页数:6
相关论文
共 18 条
[1]   Ropinirole for the treatment of early Parkinson's disease [J].
Adler, CH ;
Sethi, KD ;
Hauser, RA ;
Davis, TL ;
Hammerstad, JP ;
Bertoni, J ;
Taylor, RL ;
SanchezRamos, J ;
OBrien, CF .
NEUROLOGY, 1997, 49 (02) :393-399
[2]   Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study [J].
Block, G ;
Liss, C ;
Reines, S ;
Irr, J ;
Nibbelink, D ;
Aarli, J ;
Aguilar, M ;
Ahrens, S ;
Bakheit, A ;
Baumel, B ;
Bertoni, J ;
Capildeo, R ;
CastroCaldas, A ;
Deza, L ;
Donaldson, I ;
Franck, G ;
Fusillo, J ;
Gauthier, S ;
Gershanik, O ;
Granerus, AK ;
Hauser, RA ;
Hennessey, K ;
Hutton, JT ;
Joffe, R ;
Koller, W ;
Last, B ;
LeWitt, P ;
Mamoli, B ;
Manyam, B ;
Mark, M ;
Nakano, K ;
Nausieda, P ;
Otero, E ;
Paulson, G ;
Pinter, M ;
Reich, S ;
Rodnitzky, R ;
Sage, J ;
Sampaio, C ;
Smith, B ;
Teravainen, H ;
Tetrud, J ;
Tolosa, E ;
Ulm, G ;
Valesco, F .
EUROPEAN NEUROLOGY, 1997, 37 (01) :23-27
[3]   Implications of the 5-year CR FIRST trial [J].
Capildeo, R .
NEUROLOGY, 1998, 50 (06) :S15-S17
[4]   STEREOTAXIC VENTRAL PALLIDOTOMY FOR PARKINSONS-DISEASE [J].
DOGALI, M ;
FAZZINI, E ;
KOLODNY, E ;
EIDELBERG, D ;
STERIO, D ;
DEVINSKY, O ;
BERIC, A .
NEUROLOGY, 1995, 45 (04) :753-761
[5]  
Duvoisin R.C., 1996, PARKINSONS DIS GUIDE, V4th
[6]  
HOEHN MMM, 1992, NEUROL CLIN, V10, P331
[7]   PRAMIPEXOLE IN PATIENTS WITH EARLY PARKINSONS-DISEASE [J].
HUBBLE, JP ;
KOLLER, WC ;
CUTLER, NR ;
SRAMEK, JJ ;
FRIEDMAN, J ;
GOETZ, C ;
RANHOSKY, A ;
KORTS, D ;
ELVIN, A .
CLINICAL NEUROPHARMACOLOGY, 1995, 18 (04) :338-347
[8]   NEUROPATHOLOGICAL EVIDENCE OF GRAFT-SURVIVAL AND STRIATAL REINNERVATION AFTER THE TRANSPLANTATION OF FETAL MESENCEPHALIC TISSUE IN A PATIENT WITH PARKINSONS-DISEASE [J].
KORDOWER, JH ;
FREEMAN, TB ;
SNOW, BJ ;
VINGERHOETS, FJG ;
MUFSON, EJ ;
SANBERG, PR ;
HAUSER, RA ;
SMITH, DA ;
NAUERT, GM ;
PERL, DP ;
OLANOW, CW .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1118-1124
[9]  
Kreider Margaret, 1996, Neurology, V46, pA475
[10]   Parkinson's disease - Second of two parts [J].
Lang, AE ;
Lozano, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (16) :1130-1143